NASDAQ:LABT Lakewood-Amedex Biotherapeutics Q1 2026 Earnings Report $0.99 -0.16 (-13.93%) Closing price 09/29/2026 04:00 PM EasternExtended Trading$0.98 -0.01 (-1.50%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Lakewood-Amedex Biotherapeutics EPS ResultsActual EPS-$2.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALakewood-Amedex Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALakewood-Amedex Biotherapeutics Announcement DetailsQuarterQ1 2026Date5/22/2026TimeAfter Market ClosesConference Call DateFriday, May 22, 2026Conference Call Time8:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Lakewood-Amedex Biotherapeutics Earnings HeadlinesLakewood amedex Biotherapeutics Inc (LABT)September 29 at 8:27 AM | za.investing.comLakewood-Amedex Biotherapeutics (NASDAQ:LABT) Stock Falls 31.1% - Time to Sell?September 29 at 1:41 AM | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)LABT: First patient dosed in phase 2a trial of Nu-3 for infected diabetic foot ulcersSeptember 28 at 5:25 PM | msn.comLakewood-Amedex reports positive Nu-3 MIC data against diabetic foot ulcer clinical isolatesSeptember 28 at 12:24 PM | msn.comLakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot UlcersSeptember 28 at 8:02 AM | prnewswire.comSee More Lakewood-Amedex Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lakewood-Amedex Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lakewood-Amedex Biotherapeutics and other key companies, straight to your email. Email Address About Lakewood-Amedex BiotherapeuticsLakewood-Amedex Biotherapeutics (NASDAQ:LABT), Inc. is a biotechnology company focused on developing anti-infective therapies and products. Its research has centered on broad-spectrum antimicrobial compounds designed to address bacterial, viral and fungal pathogens while supporting topical and localized treatment applications. The company’s development portfolio has included NVC-422, also known as an Aganocide compound. NVC-422 has been evaluated for potential uses in areas such as skin infections, wound care and other conditions where topical antimicrobial treatment may be appropriate. Lakewood-Amedex has also pursued related applications for its anti-infective technology. The company is associated with operations in the United States, including Florida. Publicly available information about its current leadership, commercial operations and geographic reach is limited, and the company’s product candidates may remain subject to clinical, regulatory and commercial development requirements.View Lakewood-Amedex Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
